FOLH1 and prostate cancer: A prospective phase 2 trial (NCT03298087) is currently investigating the role of MDT in patients with newly-diagnosed M1a/b prostate cancer, with 1–5 lesions (excluding pelvic lymph nodes) based on PSMA PET-CT imaging.